A pill from Mirati Therapeutics developed to block the “undruggable” cancer protein called KRAS showed partial tumor responses in three patients with lung cancer and a single patient with colon cancer, according to preliminary results released Monday.
The first-in-human clinical data for the drug, called MRTX849, are scant — encompassing only 12 patients — but they are also significant, in that they will invigorate a debate that has simmered for months: Who has the superior KRAS-blocking drug: Mirati or Amgen?
About the Author Reprints
